Intercept Thinks Fibrosis Effect Could Carry Its NASH Candidate

With Phase II data in its pocket showing a promising reduction in fibrosis, Intercept is eager to begin Phase III study of obeticholic acid in NASH. But regulators are still uncertain about what endpoints should be used and concerns about LDL levels in Phase II have driven the firm’s stock price down.